e-learning
resources
Vienna 2003
Tuesday 30.09.2003
Modulation of bronchial hyperreactivity and immune response in the airways
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Immunomodulatory treatment of severe persistent asthma with interferon-αcon-1 (IFN-αcon-1). Effect on the clinical course of oral corticosteroid dose and eosinophil numbers
N. Bergmann, M. Foerster, A. Reissig, B. Mock, G. Workalemahu, C. Kroegel (Jena, Germany)
Source:
Annual Congress 2003 - Modulation of bronchial hyperreactivity and immune response in the airways
Session:
Modulation of bronchial hyperreactivity and immune response in the airways
Session type:
Oral Presentation
Number:
2448
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
N. Bergmann, M. Foerster, A. Reissig, B. Mock, G. Workalemahu, C. Kroegel (Jena, Germany). Immunomodulatory treatment of severe persistent asthma with interferon-αcon-1 (IFN-αcon-1). Effect on the clinical course of oral corticosteroid dose and eosinophil numbers. Eur Respir J 2003; 22: Suppl. 45, 2448
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Effect of dupilumab on oral corticosteroid use in severe asthma patients with improving lung function
Source: Virtual Congress 2020 – Recent innovations regarding the mechanisms and treatments of asthma
Year: 2020
Comparison of the effect of short course of oral prednisone in patients with moderate and severe persistent asthma
Source: Eur Respir J 2003; 22: Suppl. 45, 281s
Year: 2003
Effect of low dose theophylline as adjunct in treatment of COPD
Source: International Congress 2016 – Pharmacological management of COPD
Year: 2016
Decreasing dose protocol for omalizumab treatment in oral corticosteroid allergic asthma patients
Source: Annual Congress 2011 - Allergen immunotherapy and anti-immunoglobulin E
Year: 2011
Reducing the dose of inhaled corticosteroids (ICS) under therapy with montelukast in stable asthma: effects on lung function and inflammation
Source: Eur Respir J 2001; 18: Suppl. 33, 261s
Year: 2001
Oral corticosteroids in the treatment of exacerbation of severe asthma
Source: Virtual Congress 2020 – Exhaled biomarkers of asthma and the asthma burden
Year: 2020
Effect of oral N-acetylcysteine treatment on systemic inflammatory status in COPD patients
Source: Eur Respir J 2005; 26: Suppl. 49, 716s
Year: 2005
Omalizumab therapy reduces oral corticosteroid use in patients with severe allergic (IgE-mediated) asthma: European real-life experience
Source: Annual Congress 2009 - Severe asthma and its treatment
Year: 2009
Effect of corticosteroids on lymphocytes from severe asthma patients
Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma
Year: 2012
Expression of inflammatory cytokines following stepwise dose reduction of corticosteroids of long-term oral corticosteroids users with COPD
Source: Eur Respir J 2004; 24: Suppl. 48, 62s
Year: 2004
Effect of roflumilast on exacerbations in patients with severe COPD and a prior history of hospitalization taking combination therapy
Source: International Congress 2015 – Advances in the future treatment of COPD
Year: 2015
The oral corticosteroid sparing effect of omalizumab in paediatric patients with severe chronic asthma
Source: Annual Congress 2010 - Managing asthma and allergic disease in children
Year: 2010
Comparative effectiveness of two different doses of inhaled corticosteroid in triple therapy on exacerbations in patients with severe COPD: a real-world study
Source: Virtual Congress 2021 – Therapies for respiratory diseases in primary care and COVID - 19
Year: 2021
Long-term efficacy of 1 year anti-inflammatory treatment in paediatric patients with mild persistent asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 379s
Year: 2004
Monitoring of inflammatory changes in patients with bronchial asthma before and after oral corticosteroid treatment
Source: Annual Congress 2008 - Novel experimental approaches to understanding asthma and COPD II
Year: 2008
Therapeutic effect of low dose roxithromycin in chronic stable mild-to-moderate asthma
Source: Annual Congress 2010 - New treatments for asthma and COPD
Year: 2010
Effects of low dose inhaled theophylline (ADC4022) co-administered with budesonide on inflammatory markers, lung function, and quality of life in COPD patients
Source: Annual Congress 2009 - New drugs for airways disease
Year: 2009
Change in blood eosinophils following treatment with inhaled corticosteroids may predict long-term clinical response in COPD
Source: Eur Respir J, 55 (5) 1902119; 10.1183/13993003.02119-2019
Year: 2020
Efficacy of short-term high dose predonisolone therapy in acute exacerbation of bronchial asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 71s
Year: 2001
Association between blood eosinophil count and exacerbation risk in patients with asthma receiving medium- or high-dosage inhaled corticosteroids
Source: International Congress 2017 – Biomarker-based asthma control
Year: 2017
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept